Daiichi Sankyo : ASCO highlight briefing session materialPDF Live & On-demand Streaming

Published on 02/06/2025 at 20:18

Publicnow

Daiichi Sankyo Company, Limited

+0.28%

ASCO 2025 Highlights DAIICHI SANKYO CO., LTD. June 2nd (US)/ 3rd (JP), 2025

ASCO Highlights 2025: IR conference call

Hiroyuki Okuzawa

President and CEO

Ken Takeshita

Head of Global R&D

Mark Rutstein Head of Therapeutic Area Oncology Development

Agenda

Welcome message

R&D overview

Highlights from ASCO 2025

Q&A

Agenda

Welcome message

R&D overview

Highlights from ASCO 2025

Q&A

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on June 02, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 02, 2025 at 14:47 UTC.

Latest news about Daiichi Sankyo Company, Limited

AstraZeneca, Daiichi Sankyo Win FDA Breakthrough Therapy Designation for Breast Cancer Drug	17/07	MT
AstraZeneca: ninth breakthrough designation for Enhertu	17/07
Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer	17/07	CI
Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial	09/07	CI
Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	01/07	CI
Daiichi Sankyo Company, Limited, 2025 Earnings Call, Apr 25, 2025	24/06
Travel stocks lift UK midcaps after Israel-Iran ceasefire	24/06	RE
UK Shares Tick Up on Amazon Investment, Middle East Conflict De-escalation	24/06	MT
US approves AstraZeneca, Daiichi's treatment for lung cancer	24/06	RE
Datroway Approves in Us for EGFRm Lung Cancer	24/06	CI
AstraZeneca's Datroway Approval in US to Provide Treatment Option for Resistant Lung Cancer	24/06	MT
Bunzl trades in line; Telecom Plus profit climbs	24/06	AN
US approves AstraZeneca, Daiichi's treatment for lung cancer	24/06	RE
US approves AstraZeneca, Daiichi's treatment for lung cancer	24/06	RE
AstraZeneca Obtains US FDA Nod for Non-small Cell Lung Cancer Treatment	24/06	MT
AstraZeneca and Daiichi hail US approval of Datroway for lung cancer	24/06	AN
DATROWAY®? Approves in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	24/06	CI
Japan's Nikkei retreats from 4-month high as US-Iran tensions weigh	19/06	RE
Japan's Nikkei retreats from 4-month high as threat of US involvement in Iran conflict looms	19/06	RE
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer	18/06	CI
Merck: Phase 3 trial in prostate cancer	18/06
Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate	18/06	MT
Health Canada Approves VANFLYTA®? in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML	16/06	CI
DESTINY-Endometrial01 Phase 3 Trial Of ENHERTU® Initiated As First-Line Therapy In Patients With HER2 Expressing Primary Advanced Or Recurrent Endometrial Cancer	09/06	RE
AstraZeneca: Enhertu promising against breast cancer	05/06